[{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Fluconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ANI Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fluconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fluconazole","moa":"Cytochrome P450 51","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Sutphin Drugs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fluconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sutphin Drugs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Sutphin Drugs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutphin Drugs \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fluconazole","moa":"Cytochrome P450 51","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Fluconazol ratiopharm

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Access all COS suppliers
Check all USDMF suppliers

Contact Us
PharmaScopic.com

Fluconazol ratiopharm

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

121 API Suppliers, 23 USDMF, 13 CEP/COS, 4 JDMF, 15 EU WC, 46 KDMF, 18 NDC API, 52 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

54 Drugs in Development

54 Drugs in Development

INTERMEDIATES

8 Intermediate Suppliers

8 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

950 FDF Dossiers, 132 FDA Orange Book, 539 Europe, 39 Canada, 17 Australia, 58 South Africa, 165 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 100MG, TABLET;ORAL - 150MG, TABLET;ORAL - 200MG, TABLET;ORAL - 50MG

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 5 SPI Pharma, 5 DKSH, 1 Pharm-RX Chemical, 5 Boai NKY Pharmaceuticals Ltd, 5 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 4 Kirsch Pharma, 6 Actylis, 1 Aeon Procare, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Ashland, 14 BASF, 2 CD Formulation, 7 DFE Pharma, 8 Gangwal Chemicals, 1 Ideal Cures, 4 Ingredion Pharma Solutions, 14 Kerry, 3 Keval Exports, 11 Microlex e.U, 2 Nitika Pharmaceutical Specialities, 1 Novo Excipients, 3 Pharmatrans-Sanaq, 6 Pluviaendo, 4 Prachin Chemical, 27 Roquette, 1 Seppic, 5 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 11 Sigachi Industries, 4 Silverline Chemicals, 1 Ulanqab Kema New Material, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

55 Fillers, Diluents & Binders, 29 Direct Compression, 27 Granulation, 26 Disintegrants & Superdisintegrants, 21 Thickeners and Stabilizers, 16 Lubricants & Glidants, 12 Coating Systems & Additives, 12 Co-Processed Excipients, 12 Taste Masking, 11 Parenteral, 11 Controlled & Modified Release, 10 Solubilizers, 6 Chewable & Orodispersible Aids, 5 Film Formers & Plasticizers, 5 Rheology Modifiers, 3 API Stability Enhancers, 3 Topical, 3 Emulsifying Agents, 2 Coloring Agents, 1 Surfactant & Foaming Agents

DIGITAL CONTENT

30 News #PharmaBuzz

30 News #PharmaBuzz

GLOBAL SALES INFORMATION

22 US Medicaid Prescriptions, 496 Regulatory FDF Prices, 4 Annual Reports

MARKET PLACE

57 APIs, 24 FDF Dossiers

REF. STANDARDS & IMPURITIES

4 EDQM, 1 USP, 13 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Dr. Reddy's Laboratories

India

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Lead Product(s) : Fluconazole

Therapeutic Area : Undisclosed

Study Phase : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Bioavailability Study of Fluconazole Tablets 200 mg Under Fed Conditions

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

January 19, 2012

Lead Product(s) : Fluconazole

Therapeutic Area : Undisclosed

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Dr Reddy Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

02

Dr. Reddy's Laboratories

India

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Lead Product(s) : Fluconazole

Therapeutic Area : Undisclosed

Study Phase : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Bioavailability Study of Fluconazole Tablets 200 mg Under Fasting Conditions

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

January 19, 2012

Lead Product(s) : Fluconazole

Therapeutic Area : Undisclosed

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Dr Reddy Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

03

Lupin Ltd

India

CPhI Korea

Not Confirmed

04

Jiangsu Hengrui Medicine

China

CPhI Korea

Not Confirmed

05

Sutphin Drugs

U.S.A

CPhI Korea

Not Confirmed

06

Bristol Myers Squibb

U.S.A

CPhI Korea

Not Confirmed

07

ANI Pharmaceuticals Inc

U.S.A

CPhI Korea

Not Confirmed

08

Pharmtechnology

Belarus

CPhI Korea

Not Confirmed

09

Scynexis

U.S.A

CPhI Korea

Not Confirmed

10

Bayer AG

Germany

CPhI Korea

Not Confirmed

1
2